UK's NICE rejects Novartis' Xolair for children suffering severe persistent allergic asthma, on cost grounds
The UK's National Institute for Health and Clinical Excellence (NICE) has decided against recommending the use of Swiss drug major Novartis' Xolair (omalizumab) for children aged six to 11 years with severe, persistent allergic asthma in the National Health Service in England and Wales because it does not consider it to be a cost-effective use of NHS resources.
Omalizumab is the first in a generation of drugs for severe, difficult-to-control allergic asthma, where patients have an oversensitive immune system, and is already recommended by the NICE for use in patients aged 12 years and older, the drugmaker points out. Last month the Scottish Medicines Consortium (SMC) accepted the use of omalizumab for children in Scotland aged six to 11 with severe, persistent allergic asthma who are prescribed chronic systemic steroids, it added.
41% of UK hospital admissions for asthma are children under 14 years
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze